IQ Hedge Macro Tracker ETF (MCRO) is an exchange-traded fund that provides investors with targeted exposure to global macroeconomic trends through a rules-based, quantitative strategy focused on hedge fund replication. The fund employs proprietary models to track macro-oriented hedge fund strategies, including directional bets on interest rates, currencies, commodities, and equities; long/short positions in fixed income and credit instruments; and dynamic asset allocation across global markets to capture alpha from macroeconomic dislocations. MCRO offers daily liquidity on major U.S. exchanges, low expense ratios typical of passive ETF structures, and tax-efficient share creation/redemption mechanisms for institutional and retail investors seeking alternative investments without direct hedge fund access.
Headquartered in New York, NY, and launched in 2023 by IQ Candriam ETFs (a subsidiary of IndexIQ Advisors, LLC, under parent company sub-advisors Candriam and New York Life Investments), MCRO operates primarily in the U.S. market with global investment scope across developed and emerging economies in North America, Europe, Asia-Pacific, and Latin America. The fund targets sophisticated investors such as registered investment advisors, family offices, and high-net-worth individuals interested in low-correlation assets for portfolio diversification amid volatile economic cycles.
In the last year, MCRO underwent a significant rebranding and ticker change from its prior designation as part of IndexIQ's macro strategy suite, enhancing visibility and aligning with expanded multi-asset capabilities following a strategic partnership between Candriam and IndexIQ to integrate advanced AI-driven macro signals. The fund also announced a major asset growth milestone, surpassing $500 million in AUM in Q4 2025 amid heightened demand for macro hedge replication amid U.S. Federal Reserve policy shifts under President Trump's administration; additionally, it launched an enhanced share class with ESG overlays for European distribution and completed a seed capital infusion from New York Life to support product innovation. These developments position MCRO as a leader in the $50 billion+ liquid alternative ETF segment, emphasizing adaptive quantitative models over traditional benchmarks.